IPH 2101: Phase IIa data

Innate said data from the open-label, U.S. Phase IIa KIRMONO trial in about 30 patients with previously untreated smoldering MM showed that IV IPH2101 as monotherapy missed the primary endpoint of reducing M-protein levels. Details were not disclosed. ...